BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 21156462)

  • 1. Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study.
    Reece DE; Vesole DH; Shrestha S; Zhang MJ; Pérez WS; Dispenzieri A; Milone GA; Abidi M; Atkins H; Bashey A; Bredeson CN; Boza WB; Freytes CO; Gale RP; Gajewski JL; Gibson J; Hale GA; Kumar S; Kyle RA; Lazarus HM; McCarthy PL; Pavlovsky S; Roy V; Weisdorf DJ; Wiernik PH; Hari PN
    Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):458-63. PubMed ID: 21156462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and outcome of autologous transplantation in rare myelomas.
    Morris C; Drake M; Apperley J; Iacobelli S; van Biezen A; Bjorkstrand B; Goldschmidt H; Harousseau JL; Morgan G; de Witte T; Niederwieser D; Gahrton G;
    Haematologica; 2010 Dec; 95(12):2126-33. PubMed ID: 20971818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes.
    Sharma M; Qureshi SR; Champlin RE; Popat U; Giralt S; Qazilbash MH
    Am J Hematol; 2010 Jul; 85(7):502-4. PubMed ID: 20575022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study.
    Lawless S; Sbianchi G; Morris C; Iacobelli S; Bosman P; Blaise D; Reményi P; Byrne JL; Mayer J; Apperley J; Lund J; Kobbe G; Schaap N; Isaksson C; Lenhoff S; Basak G; Touzeau C; Wilson KMO; González Muñiz S; Scheid C; Browne P; Anagnostopoulos A; Rambaldi A; Jantunen E; Kröger N; Schönland S; Yakoub-Agha I; Garderet L
    Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):686-693. PubMed ID: 34158265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and outcome of allogeneic transplantation in IgD and nonsecretory myeloma. A report on behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
    Morris C; Iacobelli S; Gahrton G; van Biezen A; Drake M; Garderet L; Potter M; Schattenberg AV; Cornelissen JJ; Hamladji RM; Martelli M; Petersen E; Rovira M; Bandini G; Kroger N; de Witte T
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1054-8. PubMed ID: 25708221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Observation of humoral immunity reconstitution and its relationship with infection after autologous hematopoietic stem cell transplantation for patients with multiple myeloma].
    Liu JR; Li J; Shang JJ; Zheng D; Gu JL; Zou WY; Xu DR
    Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):317-22. PubMed ID: 23668204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.
    Jacobs RW; Saliba RM; Sasaki K; Farhan S; Armas A; Shah ND; Bashir Q; Qureshi S; Rondon G; Hosing C; Popat U; Parmar S; Shah JJ; Wang M; Weber DM; Thomas SK; Orlowski RZ; Champlin RE; Qazilbash MH
    Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):36-42. PubMed ID: 26702475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience.
    Chong YP; Kim S; Ko OB; Koo JE; Lee D; Park SH; Park SJ; Lee D; Kim SW; Suh C
    J Korean Med Sci; 2008 Oct; 23(5):819-24. PubMed ID: 18955788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
    Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
    Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Survival Outcome Associated with the Use of Novel Agents and Autologous Stem Cell Transplantation in Cases of Immunoglobulin D Multiple Myeloma in Korea.
    Kang J; Hong JY; Yoon DH; Kim S; Lee KM; Park JS; Park CJ; Min WK; Seo EJ; Jang S; Suh C
    Acta Haematol; 2018; 139(3):185-192. PubMed ID: 29635247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
    Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
    Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma.
    Munshi PN; Vesole D; Jurczyszyn A; Zaucha JM; St Martin A; Davila O; Agrawal V; Badawy SM; Battiwalla M; Chhabra S; Copelan E; Kharfan-Dabaja MA; Farhadfar N; Ganguly S; Hashmi S; Krem MM; Lazarus HM; Malek E; Meehan K; Murthy HS; Nishihori T; Olin RL; Olsson RF; Schriber J; Seo S; Shah G; Solh M; Tay J; Kumar S; Qazilbash MH; Shah N; Hari PN; D'Souza A
    Cancer; 2020 Dec; 126(23):5077-5087. PubMed ID: 32965680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.
    Sasaki K; Lu G; Saliba RM; Bashir Q; Hosing C; Popat U; Shah N; Parmar S; Dinh Y; Ahmed S; Shpall EJ; Kebriaei P; Shah JJ; Orlowski RZ; Champlin R; Qazilbash MH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1227-32. PubMed ID: 23733001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
    Björkstrand B; Iacobelli S; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Musto P; Beksac M; Bosi A; Milone G; Corradini P; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Gahrton G
    J Clin Oncol; 2011 Aug; 29(22):3016-22. PubMed ID: 21730266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.
    Scott EC; Hari P; Sharma M; Le-Rademacher J; Huang J; Vogl D; Abidi M; Beitinjaneh A; Fung H; Ganguly S; Hildebrandt G; Holmberg L; Kalaycio M; Kumar S; Kyle R; Lazarus H; Lee C; Maziarz RT; Meehan K; Mikhael J; Nishihori T; Ramanathan M; Usmani S; Tay J; Vesole D; Wirk B; Yared J; Savani BN; Gasparetto C; Krishnan A; Mark T; Nieto Y; D'Souza A
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1893-1899. PubMed ID: 27496215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma.
    Maisnar V; Hájek R; Scudla V; Gregora E; Büchler T; Tichý M; Kotoucek P; Kafková A; Forraiová L; Minarík J; Radocha J; Bláha V; Malý J
    Bone Marrow Transplant; 2008 Jan; 41(1):51-4. PubMed ID: 17934529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose Therapy and Autologous Hematopoietic Cell Transplantation as Consolidation Treatment for Primary Effusion Lymphoma.
    Mirza AS; Dholaria BR; Hussaini M; Mushtaq S; Horna P; Ravindran A; Kumar A; Ayala E; Kharfan-Dabaja MA; Bello C; Chavez JC; Sokol L
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e513-e520. PubMed ID: 31253594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis.
    Saini N; Ma J; Milton DR; Patel R; Varma A; Bashir Q; Delgado R; Mukherjee A; Rondon G; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Tang G; Mehta R; Srour S; Khouri IF; Iyer S; Weber DM; Thomas SK; Lee HC; Manasanch EE; Patel KK; Orlowski RZ; Champlin RE; Qazilbash MH
    Clin Cancer Res; 2019 Nov; 25(22):6781-6787. PubMed ID: 31481508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
    Kyle RA
    Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.